Product Description
TAS-205 is a selective hematopoietic prostaglandin D synthase (HPGDS) inhibitor discovered by Taiho Pharmaceutical. It is under development as a DMD treatment that controls the decline in motor function in DMD patients by inhibiting HPGDS, which exacerbates the inflammatory response in DMD patientsÕ muscles.Ê (Sourced from: https://www.taiho.co.jp/en/release/2019/20191209.html)
Mechanisms of Action: HPGDS Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Taiko Co
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Muscular Dystrophy, Duchenne
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04587908 |
NCT04587908 | P3 |
Active, not recruiting |
Muscular Dystrophy, Duchenne |
2027-05-01 |
22% |
2024-08-15 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
jRCT2071230127 |
jRCT2071230127 | P1 |
Recruiting |
Healthy Volunteers |
2024-12-31 |
|||
jRCT2071230028 |
jRCT2071230028 | P1 |
Recruiting |
Muscular Dystrophy, Duchenne |
2023-12-31 |
|||
jRCT2041200055 |
jRCT2041200055 | P3 |
Recruiting |
Muscular Dystrophy, Duchenne |
1970-01-01 |